Phase I
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
GeoVax Labs, Inc. announced its participation in a planned clinical trial led by researchers at American Gene Technologies, to develop a therapy aimed at eliminating HIV from infected people..
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
Calls for increased transparency in clinical trials have been growing and now many medical journals are requiring authors of submitted papers to disclose whether or not they will be sharing clinical trial results.
Porton Biopharma Ltd has announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase.
Last week was busy for clinical trial news. Here’s a look.
Findings further validate Cell Pouch and therapeutic cell performance in
Auris Medical Holding Ltd. announced positive interim results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence.
Faron Pharmaceuticals Oy announces feedback from the MATINS study data monitoring committee from the ongoing dose escalation study from part I of the MATINS trial.
Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumeral dystrophy.
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
PRESS RELEASES